23
Sep
2021
J&J Bounces Back, Illumina-Grail Scrutiny, & AZ’s HER-2 ADC Triumph
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Sep
2021
A Magical Time in the Presidential Range, Giving Back to Community
The Timmerman Traverse for Life Science Cares was everything I dreamed it would be. Here’s a quick recap: The team of 20 raised $706,000 to fight poverty 51 sponsors participated About 530 individuals contributed We lucked out with the weather For those unfamiliar, the Timmerman Traverse for Life Science Cares brought together a team of 20 biotech executives and investors... Read More
12
Sep
2021
Turning Around COVID Diagnostics. Mara Aspinall on The Long Run
Today’s guest on The Long Run is Mara Aspinall. Mara is a veteran diagnostics executive, investor, and educator. She’s a venture investor with Bluestone Venture Partners, the CEO of Health Catalysts (a consulting firm), and the co-founder and professor of the practice of biomedical diagnostics at Arizona State University. It’s the only program of its kind in the country, designed... Read More
9
Sep
2021
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2021
Base Editing for Therapeutics: John Evans on The Long Run
John Evans is today’s guest on The Long Run. John is the CEO of Cambridge, Mass.-based Beam Therapeutics. The company was founded a little over three years ago to develop several types of DNA base editing developed in David Liu’s lab at Harvard University, along with an RNA base editor platform developed by Feng Zhang, at the Broad Institute of... Read More
2
Sep
2021
UK ‘Gamechanger’ for Heart Disease, J&J HIV Vaccine Fails, & Purdue Dissolves
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Aug
2021
Meet the Climb to Fight Cancer Postdoctoral Fellow: Aleena Arakaki
I’m excited to announce that the first Climb to Fight Cancer postdoctoral fellow has been selected. This is a position designed to advance the careers of young scientists from traditionally underrepresented minority groups. Aleena Arakaki is the first recipient of this postdoctoral award. She is a Kanaka Maoli (Native Hawaiian) woman. Before describing Arakaki’s background and research, here’s what the... Read More
31
Aug
2021
Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Aug
2021
Pfizer / BioNTech Vaccine Approved, Lilly Works With Lycia, & We Wait for J&J
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2021
Giving Back and Experiencing Nature
Sometimes we need to get away from work, and the news, to recharge our batteries. August is traditionally that time of year for me. I just got back from the summit of Mt. Baker (elevation 10,781 ft) in the North Cascades of Washington. It was another successful mountain trip with terrific biotech people – entrepreneur Julia Owens, investor Dan Bradbury,... Read More
9
Aug
2021
Better Cancer Drugs for Kids: Julie Grant and Sam Blackman on The Long Run
Today we have a pair of guests on The Long Run — Julie Grant and Sam Blackman. Julie is a venture capitalist – a general partner at Canaan Partners. Sam is a pediatric oncologist and drug developer. After a routine business meeting, they realized they had something in common. They both believed that the pharmaceutical industry can — and should... Read More
5
Aug
2021
Bayer Snaps Up Vividion, Sanofi Grabs Translate Bio, and RIP: Tachi Yamada
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2021
Tachi Yamada, Physician-Scientist-Biopharma Industry Leader, Dies at 76
Tadataka “Tachi” Yamada, a distinguished physician-scientist who became a biopharmaceutical industry leader and a deeply respected advisor to biotech entrepreneurs, died the morning of Aug. 4. He was 76. Yamada died from a heart attack while exercising at home in Seattle, said his son, Takao. “He was a special person who did things to help people. That was his North... Read More
29
Jul
2021
FDA Rejections, Midsummer IPOs & Amgen’s Bispecific Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jul
2021
Career Arc of a Biotech Leader: Sue Desmond-Hellmann on The Long Run
Today’s guest on The Long Run is Sue Desmond-Hellmann. Sue — and I don’t say this about many people — is a biotech industry legend. Sue is an oncologist and a public health professional by training. She made her name in biopharmaceuticals at Genentech from 1995-2009 — the glory days when it became the world’s most important developer of new... Read More
22
Jul
2021
Biogen’s Bumbling Defense, Delta on the Move, & PacBio’s Power Play
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jul
2021
Investing at the Nexus of Biology & Technology: Jenny Rooke on The Long Run
Today’s guest on The Long Run is Jenny Rooke. Jenny is the founder and managing partner of San Francisco-based Genoa Ventures. I’ve been wanting to invite Jenny on the podcast for a while. Back in 2018, I profiled her as one of “Nine VCs Who Matter, But You Never Read About.” As I wrote then: “VCs take on lots of... Read More
15
Jul
2021
Payers Revolt Against Biogen’s Aduhelm, FDA Credibility Crisis, and a Prime Financing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jul
2021
Verge Genomics Strikes Deal with Lilly to Validate New Targets for ALS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2021
Biogen’s Perilous Path, Intellia’s In Vivo Milestone, & Holiday Financings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.